SHORT REPORTSAtherosclerosis in Alaska Natives and non-natives
Abstract
Low mortality from coronary heart disease (CH D) among Eskimos has been attributed to less atherosclerosis in the coronary arteries because of a high dietary intake of omega-3 fatty acids. Other investigators attribute this low mortality to the fact that Eskimos have a high mortality from other causes before middle age, when CH D is common. However, most studies have been epidemiological, either by death-certificate review or risk-factor evaluation. We evaluated the extent of atherosclerotic lesions in the coronary arteries and aortas from Alaska Natives. Standardised comparisons between samples from 103 Native and 101 non-native residents show that the extent of raised lesions increases with age in both groups, but the prevalence of raised lesions in native specimens was consistently lower than in those from non-natives. This difference was statistically significant. The data suggest that the differences in CHD mortality between Alaska Natives and non-natives are, at least in part, the result of less atherosclerosis in natives.
References (10)
- Ho Bang et al.
Plasma lipid and lipoprotein pattern in Greenlandic west coast Eskimos
Lancet
(1971) - Ho Bang et al.
Lipid metabolism and ischemic heart disease in Greenland Eskimos
Adv Nutr Res
(1980) - P. Bjerregaard et al.
Mortality from ischaemic heart disease and cerebrovascular disease in Greenland
Int J Epidemiol
(1988) - JP. Middaugh
Cardiovascular deaths among Alaskan natives, 1980-86
Am J Public Health
(1990)
Cited by (137)
Effects of culinary treatments on the lipid nutritional quality of fish and shellfish
2023, Food Chemistry: XCoronary heart disease (CHD) is one of the leading causes of death worldwide. Seafood, especially fish and shellfish, is a healthy food that reduces the risk of CHD. In many regions, seafood is consumed cooked to eliminate potentially pathogenic microorganisms. Although there have been many reports of culinary preparations causing changes in the fatty acid profile of fish and shellfish, this information has not been well organized, and most of it is not associated to CHD. Therefore, this study was conducted to study the effect of culinary treatments of seafood on lipid nutritional quality in relation to promotion/prevention of CHD. In this study, fatty acid profiles of fish and shellfish prepared with different culinary preparations were obtained from published literature. Lipid nutritional quality indices related to promoting/preventing CHD were calculated and analyzed to reveal the effects of culinary treatment on the lipid nutritional quality of fish and shellfish in promoting/preventing of CHD. The information in this article is very useful and can fill the knowledge gap of the effects of culinary preparation on the lipid nutritional quality of fish and shellfish. Such information is very useful for guiding consumers to choose better ways to cook fish and shellfish to reduce the risk of CHD.
Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω-3 and ω-6 PUFAs
2023, Advances in PharmacologyThe seminal discovery that cytochrome P450 enzymes (CYPs) can oxidize polyunsaturated fatty acids (PUFAs) sparked a new area of research aimed at discovering the role of these metabolites in cardiac physiology and pathophysiology. CYPs metabolize arachidonic acid, an ω-6 PUFA, to alcohols and epoxides with the latter providing cardioprotection following myocardial infarction, hypertrophy, and diabetes-induced cardiomyopathy through their anti-inflammatory, vasodilatory and antioxidant properties. Despite their protective properties, the use of EETs as therapeutic agents is hampered mainly by their rapid hydrolysis to less active vicinal diols by soluble epoxide hydrolase (sEH). Several approaches have been investigated to prolong EET signaling effects using small molecule sEH inhibitors, chemically and biologically stable analogs of EETs and more recently, through the development of an sEH vaccine. Alternatively, research investigating the cardioprotective outcomes of ω-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), mainly focused on dietary intake or supplementation studies. EPA and DHA have overlapping but distinct effects on myocardial function and merit separate studies to fully understand their mechanism of cardiac protection. In contrast to EETs, relatively fewer studies examined the protective mechanisms of EPA and DHA derived epoxides to determine if some protective effects are in part due to the CYP mediated downstream metabolites. The actions of CYPs on PUFAs generate potent oxylipins utilizing diverse cardioprotective mechanisms and the extent of their full potential will be important for the future development of therapeutics to prevent or treat cardiovascular disease.
Omega-3 and cardiovascular prevention – Is this still a choice?
2022, Pharmacological ResearchThere is currently growing attention being paid to the role of elevated triglycerides (TGs) as important mediators of residual atherosclerotic cardiovascular disease (ASCVD) risk. This role is supported by genetic studies and by the persistent residual risk of ASCVD, even after intensive statin therapy. Although TG lowering drugs have shown conflicting results when tested in cardiovascular outcome trials, data from the REDUCE-IT study with the ethyl ester of ω-3 eicosapentaenoic acid (EPA) have revived hope in this area of research. The aim of the present review is to critically discuss the most recent large trials with ω-3 fatty acids (FAs) trying to elucidate mechanistic and trial-related differences, as in the case of REDUCE-IT and STRENGTH studies. The ω-3 FAs may lower cardiovascular risk through a number of pleiotropic mechanisms, e.g., by lowering blood pressure, by mediating antithrombotic effects, by providing precursors for the synthesis of specialized proresolving mediators that can inhibit inflammation or by modulating the lipid rafts enriched in cholesterol and sphingolipids. In conclusion, in a field fraught with uncertainties, the ω-3 FAs and especially high dose icosapent ethyl (the ethyl ester of EPA) are at present a most valuable therapeutic option to reduce the ASCVD risk.
Marine lipids and diabetes
2022, Advances in Dietary Lipids and Human HealthMany epidemiological and clinical studies have been conducted to examine the potential effects of marine n-3 polyunsaturated fatty acids (PUFAs) on the prevention and management of diabetes and related metabolic risk factors. Although marine n-3 PUFAs are inversely associated with diabetes in early ecological and cross-sectional studies, evidence from prospective cohort studies or randomized controlled trials is still inconsistent. Some studies suggest that marine n-3 PUFAs may be associated with lower diabetes risk among Asian, but not Western, populations. Trial evidence supports the beneficial effect of marine n-3 PUFAs on blood triacylglycerol, but not glycemic, traits. Integration of nutrigenetics in future research may help disentangle the relationship between marine n-3 PUFAs and diabetes. This chapter aims to discuss the epidemiological and clinical evidence of marine n-3 PUFAs for the prevention and management of diabetes.
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
2020, American Journal of Preventive CardiologyA causal relationship between elevated triglycerides and cardiovascular disease is controversial, as trials of triglyceride-lowering treatments have not shown significant impact on cardiovascular outcomes. However, hypertriglyceridemia is associated with atherogenesis and risk for acute cardiovascular events that persist despite optimal statin treatment. Although most trials of triglyceride-lowering treatments have been negative, in trials of niacin and fibrates, subgroup analyses in patients with higher baseline triglycerides and lower HDL-C levels suggest reduced incidence of cardiovascular endpoints. The REDUCE-IT trial demonstrated that addition of purified prescription eicosapentaenoic acid (icosapent ethyl) 4 g/day in high-risk patients with triglyceride levels 135–499 mg/dL and optimized statin treatment significantly reduced cardiovascular events versus placebo (hazard ratio 0.75; 95% confidence interval 0.68–0.83; P < 0.001). Benefit was seen regardless of baseline and on-treatment triglyceride levels, suggesting that other effects of eicosapentaenoic acid besides triglyceride reduction may have played a role.
Long chain n-3 polyunsaturated fatty acids and cardiovascular risk: A bad trial of inefficiency
2018, Cahiers de Nutrition et de DietetiqueCette mise au point a pour objectifs de préciser sur la base des essais récents et en particulier des nouvelles méta-analyses l’état des lieux sur ce sujet ainsi que les mécanismes qui sous-tendent ces effets. L’épidémiologie met en évidence une très faible prévalence de cardiopathie ischémique chez les Inuits dans les années 50–70. Les travaux de Bang & Dyerberg dans les années 70 les ont conduits à proposer l’hypothèse que la teneur élevée en AGPI-LC n-3 de l’alimentation traditionnelle des Inuits était susceptible d’expliquer ce constat épidémiologique ; le mécanisme invoqué était la moindre agrégabilité plaquettaire. L’occidentalisation ultérieure du mode de vie des Inuits rend compte de l’augmentation de leur risque cardiovasculaire à partir des années 80. De l’ensemble des études de cohorte et des essais cliniques randomisés (ECRs), il apparaît que si les effets préventifs des AGPI-LC n-3 en prévention primaire ne sont pas formellement établis, leur effet protecteur en prévention secondaire est bien réel, du moins pour un apport > 1 g/j d’EPA + DHA et plus particulièrement chez des patients avec hypertriglycéridémie (> 1,50 g/l) et/ou avec LDL cholestérol élevé (> 1,30 g/L), et ce alors même que ces patients ont un traitement médicamenteux de plus en plus conséquent destiné à éviter la récidive d’événements cardiovasculaires. Récemment, à côté des conseils nutritionnels d’une augmentation des apports en produits d’origine marine susceptible de permettre d’atteindre un niveau > 1 g/j d’EPA + DHA, ont été développés, des compléments hautement purifiés et concentrés d’EPA ± DHA. Aux États-Unis, de nouvelles formes pharmaceutiques ont été acceptées par la FDA pour le traitement de l’hypertriglycéridémie à la dose quotidienne de 4 g. Des ECRs avec ces nouvelles formes sont en cours pour apprécier leur bénéfice potentiel en prévention primaire ou secondaire.
The purpose of this review is to specify, on the basis of recent studies and in particular of new meta-analyses, the state of art on this subject and the mechanisms underlying these effects. Epidemiology shows a very low prevalence of ischemic heart disease among Inuit in the 50s–70s. Bang & Dyerberg's studies in the 1970s led them to propose the hypothesis that the high levels of n-3 LC-PUFA in traditional Inuit diet were likely to explain this epidemiological finding; the mechanism invoked was the least platelet aggregation. The subsequent westernization of the Inuit lifestyle reflects their increased cardiovascular risk from the 80s. From all cohort studies and randomized clinical trials (RCTs), it appears that if the preventive effects of n-3 LC-PUFA in primary prevention are not formally established, their protective effect in secondary prevention is very real, at least for an intake > 1 g/d of EPA + DHA and more particularly in patients with hypertriglyceridemia (> 1.50 g/L) and/or with a high LDL cholesterol (> 1.30 g/L), even though these patients are treated with many drugs aiming to protect them for a new cardiovascular event. Recently, in addition to nutritional advice on increasing the intake of marine products to reach a daily level > 1 g of EPA + DHA, highly purified and concentrated supplements of EPA ± DHA have been developed. In the USA, new pharmaceutical forms have been accepted by the FDA for the treatment of hypertriglyceridemia at the daily dose of 4 g. RCTs with these new forms are underway to assess their potential benefit in primary or secondary prevention.